Evidence map›Paper›PMID 22859931›Full record

ArticlePloS one2012

Proline-rich tyrosine kinase 2 (Pyk2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells.

Marco Genua, Shi-Qiong Xu, Simone Buraschi, Stephen C Peiper, Leonard G Gomella, Antonino Belfiore, Renato V Iozzo, Andrea Morrione

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Role of Pyk2 in Human Cancers.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Marco GenuaEndocrine Mechanisms and Hormone Action Program, Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Shi-Qiong Xu
Simone Buraschi
Stephen C Peiper
Leonard G Gomella
Antonino Belfiore
Renato V Iozzo
Andrea Morrione
Sidney Kimmel Cancer Center · USThomas Jefferson University · USMagna Graecia University · IT

Funding

NEOPLASTIC MODULATION OF PROTEOGLYCAN METABOLISMR01CA039481 · NCI · UNIVERSITY OF PENNSYLVANIA · PI IOZZO, RENATO V. · 1985 to 2020
$7.1M
The Biology of Perlecan in Cancer and AngiogenesisR01CA047282 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 1990 to 2019
$5.7M
Proepithelin Signaling in Urothelial CellsR01DK068419 · NIDDK · THOMAS JEFFERSON UNIVERSITY · PI MORRIONE, ANDREA · 2005 to 2009
$1.2M
NCI NIH HHS R01 CA039481NCI NIH HHS R01 CA047282NCI NIH HHS R01 CA39481NIDDK NIH HHS R01 DK068419
6 · The paper itself

Abstract

The insulin-like growth factor receptor I (IGF-IR) plays an essential role in transformation by promoting cell growth and protecting cancer cells from apoptosis. We have recently demonstrated that the IGF-IR is overexpressed in invasive bladder cancer tissues and promotes motility and invasion of urothelial carcinoma cells. These effects require IGF-I-induced Akt- and MAPK-dependent activation of paxillin. The latter co-localizes with focal adhesion kinases (FAK) at dynamic focal adhesions and is critical for promoting motility of urothelial cancer cells. FAK and its homolog Proline-rich tyrosine kinase 2 (Pyk2) modulate paxillin activation; however, their role in regulating IGF-IR-dependent signaling and motility in bladder cancer has not been established. In this study we demonstrate that FAK was not required for IGF-IR-dependent signaling and motility of invasive urothelial carcinoma cells. On the contrary, Pyk2, which was strongly activated by IGF-I, was critical for IGF-IR-dependent motility and invasion and regulated IGF-I-dependent activation of the Akt and MAPK pathways. Using immunofluorescence and AQUA analysis we further discovered that Pyk2 was overexpressed in bladder cancer tissues as compared to normal tissue controls. Significantly, in urothelial carcinoma tissues there was increased Pyk2 localization in the nuclei as compared to normal tissue controls. These results provide the first evidence of a specific Pyk2 activity in regulating IGF-IR-dependent motility and invasion of bladder cancer cells suggesting that Pyk2 and the IGF-IR may play a critical role in the invasive phenotype in urothelial neoplasia. In addition, Pyk2 and the IGF-IR may serve as novel biomarkers with diagnostic and prognostic significance in bladder cancer.

Indexed as

CarcinomaCell Line, TumorCell MovementFocal Adhesion Kinase 1Focal Adhesion Kinase 2Focal AdhesionsGRB2 Adaptor ProteinHumansInsulin-Like Growth Factor IInsulin Receptor Substrate ProteinsMitogen-Activated Protein KinasesNeoplasm InvasivenessPaxillinProto-Oncogene Proteins c-aktReceptor, IGF Type 1Signal TransductionFocal Adhesion Kinase 1Focal Adhesion Kinase 2GRB2 Adaptor ProteinGRB2 protein, humanInsulin-Like Growth Factor IInsulin Receptor Substrate ProteinsIRS1 protein, humanIRS2 protein, humanMitogen-Activated Protein KinasesPaxillinProto-Oncogene Proteins c-aktPTK2 protein, humanReceptor, IGF Type 1

Identifiers

PMID22859931
PMCPMC3408023
OpenAlexW2087795951

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.